Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Lutikizumab (anti-IL1a & IL1b) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab (anti-IL1a & IL1b) binds and inhibits IL-1α and IL-1β. Lutikizumab (anti-IL1a & IL1b) can be used for the research of osteoarthritis.
Purity
≥90% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg
Lutikizumab (anti-IL1a&IL1b) (Ab175588) - ELISA
Immobilized Recombinant Human IL-1 alpha protein (rp156178) at 1.0 μg/mL can bind Lutikizumab (anti-IL1a&IL1b) (Ab175588) with the EC50 of 38.93 ng/mL.
Lutikizumab (anti-IL1a&IL1b) (Ab175588) - SEC
The purity of Lutikizumab (anti-IL1a&IL1b) (Ab175588) is more than 95% verified by HPLC.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
